Repligen Corporation (RGEN) › Analysis

Repligen (RGEN) stock analysis, November 17, 2026: Pullback oversold, bullish but low conviction

Published November 17, 2026 · RGEN chart, levels and live analysis

Repligen Corporation (RGEN) has slipped into a sharp five‑day pullback that has pushed the price into oversold territory while the broader market and its health‑care sector peers have lagged behind. The weekly uptrend remains intact, the price still sits above its 40‑week average, and a daily close above $174.88 on volume above the 20‑day average would be the first sign of a renewed upside move. The balance of evidence leans bullish for the next two to six weeks, but conviction stays low because the breakout math does not yet meet a 3‑to‑1 reward‑to‑risk ratio.

Why it matters

The most recent catalyst was the filing of a Form 10‑Q on October 30 that disclosed a net loss of $38.4 million, a 358 % year‑over‑year decline, and a diluted EPS of –$0.68 SEC EDGAR. The market absorbed the loss without a dramatic price swing, suggesting the downside was largely priced in. At the same time, the company announced a $1 billion private convertible senior notes transaction, swapping its 2028 notes for new 0.25 % notes due 2031 GlobeNewswire. The financing move was viewed as a balance‑sheet stabilizer rather than a growth driver, and the stock’s reaction was muted.

Sector‑wide, health‑care has outperformed the S&P 500 over the past month, gaining 5.4 % versus the index’s 3.4 % rise SEC EDGAR. Yet RGEN has underperformed both the market (–5.0 % versus S&P 500 over 50 days) and its health‑care ETF XLV (–13.6 % versus XLV over 50 days). The five‑day attribution numbers show the stock fell 6.68 % while the market fell 1.68 % and XLV fell 1.40 %, leaving a stock‑minus‑sector drag of roughly 5.3 %.

Analyst consensus remains a “buy” with a mean price target of $203.2, a low target of $175 and a high of $235 SEC EDGAR. The current price of $162.37 is about 20 % below the mean target, indicating a sizable valuation gap that the market has not yet closed. No new commentary in the news debate has emerged to challenge the consensus, and the recent press releases have been neutral in tone.

Overall, the move has been driven more by stock‑specific weakness than by a sector rotation. The health‑care sector’s relative strength has not been enough to lift RGEN, and the broader market’s modest decline has added a small negative bias.

What the evidence says

On the long‑term view, the weekly uptrend is still intact and the price remains above its 40‑week moving average, keeping the original bullish thesis alive. The stock is trading well within its 52‑week range, 16.5 % below the high of $194.57 and 57.8 % above the low of $102.87, indicating ample room for upside if the trend resumes.

For the next two to six weeks, the balance of evidence leans positive. The assessment flags a bullish stance with low conviction because the pullback has entered oversold territory (RSI 14 at 39.8) and the weekly trend is still upward. The breakout math requires a daily close above $174.88 on volume above the 20‑day average to validate an upside move, but the reward‑to‑risk ratio to the first target of $176.93 is only 0.1 : 1, far short of the 3 : 1 threshold. The strongest case against a near‑term rally is the stock’s recent underperformance versus both the S&P 500 and XLV, and the volume today is 95.5 % below its 20‑day average, indicating weak buying pressure. These factors keep conviction low.

Levels that matter

The structure holds above the swing‑zone support at $156.91; a break below that would signal the first crack in the weekly trend. The trend would be considered ended if the price fell below the 200‑day SMA at $145.39 on a weekly close, a level that also marks the next picture‑change trigger.

The breakout level is $174.88, the top of the swing‑zone. A close above this price on volume exceeding the 20‑day average would meet the breakout condition. The math projects two targets: $176.93 (the 50‑day SMA) with a reward‑to‑risk of 0.1 : 1, and $194.57 (the 52‑week high) with a reward‑to‑risk of 1 : 1. Because the reward‑to‑risk does not reach 3 : 1, the price would need to move to roughly $182 to achieve a 3 : 1 ratio from the stop at $154.93.

What would change the picture

A weekly close below the 200‑day SMA at $145.39 would invalidate the current bullish reading and signal a trend reversal. Conversely, any material corporate development—such as a new partnership, a positive earnings surprise, or a clear path to profitability—could shift sentiment and accelerate a move above the breakout level.

What to watch

Get a message when the RGEN picture changes — the agent team watches the levels and the news for you.Create a free account

More RGEN analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.